Dataset Information

Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome?

ABSTRACT:

Background and objective

The antisecretory factor (AF) exerts antisecretory and anti-inflammatory properties in the bowel. The aim of this study was to evaluate the effect of exogenous AF (Salovum) or cereals stimulating the endogenous AF (SPC-Flakes), given alone or in combination, in patients with short bowel syndrome (SBS).

Methods

Patients received Salovum alone at T₀?-T₁, Salovum plus SPC-Flakes at T₁?-T₂, and SPC-Flakes alone at T₂?-T₃. At T₀ and T₃, water balance, weight, lean mass (FFM), total body water (TBW), extracellular water (ECW), and nutritional and inflammatory biochemical parameters were evaluated. The water balance was also measured at T₁, T₂, and 30?days (T_S) from the end of treatment.

Results

Among the 7 patients enrolled, 2 discontinued treatment due to side effects and 1 was excluded after a cancer was diagnosed. Salovum alone or with SPC-Flakes did not improve the intestinal absorption in patients with SBS, while the administration of SPC-Flakes alone lead towards a trend of increased faecal volume. Weight, FFM, TBW, and ECW, as well as nutritional and inflammatory status, did not statistically change at the end of treatment (T₃) as compared with T₀. At T_S water balance was restored.

Conclusion

The administration of exogenous AF or the stimulation of endogenous AF seems to be unable to offer an effective therapy in patients with SBS. On the contrary, their administration appears to aggravate fluid loss and induce side effects.

SUBMITTER: Viggiani MT

PROVIDER: S-EPMC6537051 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome?

Viggiani Maria Teresa MT Di Leo Alfredo A Barone Michele M

Nutrition and metabolic insights 20190523

<h4>Background and objective</h4>The antisecretory factor (AF) exerts antisecretory and anti-inflammatory properties in the bowel. The aim of this study was to evaluate the effect of exogenous AF (Salovum) or cereals stimulating the endogenous AF (SPC-Flakes), given alone or in combination, in patients with short bowel syndrome (SBS).<h4>Methods</h4>Patients received Salovum alone at T<sub>0</sub> -T<sub>1</sub>, Salovum plus SPC-Flakes at T<sub>1</sub> -T<sub>2</sub>, and SPC-Flakes alone at T< ...[more]

PMID: 31205420

Similar Datasets

Project description:IntroductionParenteral nutrition (PN) dependence in short bowel syndrome (SBS) patients is linked to the functionality of the remnant small bowel (RSB). Patients may wean off PN following a period of intestinal adaptation that restores this functionality. Currently, plasma citrulline is the standard biomarker for monitoring intestinal functionality and adaptation. However, available studies reveal that the relationship the biomarker with the length and function of the RSB is arguable. Thus, having additional biomarkers would improve pointing out PN weaning.AimBy measuring concomitant changes in citrulline and the novel biomarker apolipoprotein AIV (Apo AIV), as well as taking into account the anatomy of the RSB, this exploratory study aims to a better understanding of the intestinal adaptation process and characterization of the SBS patients under PN.MethodsThirty four adult SBS patients were selected and assigned to adapted (aSBS) and non-adapted (nSBS) groups after reconstructive surgeries. Remaining jejunum and ileum lengths were recorded. The aSBS patients were either on an oral diet (ORAL group), those with intestinal insufficiency, or on oral and home parenteral nutrition (HPN group), those with chronic intestinal failure. Apo AIV and citrulline were analyzed in plasma samples after overnight fasting. An exploratory ROC analysis using citrulline as gold standard was performed.ResultsBiomarkers, Apo AIV and citrulline showed a significant correlation with RSBL in aSBS patients. In jejuno-ileocolic patients, only Apo AIV correlated with RSBL (rb = 0.54) and with ileum length (rb = 0.84). In patients without ileum neither biomarker showed any correlation with RSBL. ROC analysis indicated the Apo AIV cut-off value to be 4.6 mg /100 mL for differentiating between the aSBS HPN and ORAL groups.ConclusionsTherefore, in addition to citrulline, Apo AIV can be set as a biomarker to monitor intestinal adaptation in SBS patients. As short bowel anatomy is shown to influence citrulline and Apo AIV plasma values, both biomarkers complement each other furnishing a new insight to manage PN dependence.

Dataset Information

Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome?

Background and objective

Methods

Results

Conclusion

Publications

Can the Antisecretory Factor Be Considered a New Therapy for the Short Bowel Syndrome?

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets